Loading…
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study
Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinic...
Saved in:
| Published in: | Journal of Crohn's and colitis 2010-12, Vol.4 (6), p.629-636 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083 |
| container_end_page | 636 |
| container_issue | 6 |
| container_start_page | 629 |
| container_title | Journal of Crohn's and colitis |
| container_volume | 4 |
| creator | Nunes, Tiago Barreiro-de Acosta, Manuel Nos, Pilar Marin-Jiménez, Ignacio Bermejo, Fernando Ceballos, Daniel Iglesias, Eva Gomez-Senent, Silvia Torres, Yolanda Ponferrada, Angel Arevalo, José A Hernandez, Vicent Calvet, Xavier Ginard, Daniel Monfort, David Chaparro, Maria Manceñido, Noemi Domínguez-Antonaya, Mercedes Villalón, César Perez-Calle, José L Muñoz, Carmen Nuñez, Henar Carpio, Daniel Aramendiz, Roberto Bujanda, Luis Estrada-Oncins, Silvia Hermida, Carlos Barrio, Jesus Casis, M Begoña Dueñas-Sadornil, M Carmen Fernández, Luis Calvo-Cenizo, M Mar Botella, Belen de Francisco, Ruth Ayala, Edgar Sans, Miquel |
| description | Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice.
Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response.
BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p |
| doi_str_mv | 10.1016/j.crohns.2010.07.003 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_818639674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>818639674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083</originalsourceid><addsrcrecordid>eNo9kEtr3DAUhUVIaR7tPwhFu6w80cPWo7sy5AUDgbSzFrJ8TTTI1lSSA1n3j9eeSbK6h8s553I_hK4oWVFCxc1u5VJ8GfOKkXlF5IoQfoLOqZKiqmupTw-aV1rX4gxd5LwjpNGNVF_RGaOUsUayc_Rvm6Gfwgg549jjmGzALbgQByg2xxFw5_cp7n0cbQHsR1xeAJcEtgwwliVjXfGvgKfgINmDdDH44vPidsGP3s2l-7T4HPw8FDzfrjeP6y3-Xabu7Rv60tuQ4fv7vETbu9s_64dq83T_uP61qRxvWKk60IoykIq7FnjPrCKEOQaUqdYCVdQ2tAUreimF7q1uaiZE2_SCC806ovgluj72zg_9nSAXM_jsIAQ7QpyyUVQJroWsZ2d9dM6Ic07Qm33yg01vhhKz0Dc7c6RvFvqGSDPTn2M_3g9M7QDdZ-gDN_8Pz9qEsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>818639674</pqid></control><display><type>article</type><title>Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study</title><source>Oxford Journals Online</source><creator>Nunes, Tiago ; Barreiro-de Acosta, Manuel ; Nos, Pilar ; Marin-Jiménez, Ignacio ; Bermejo, Fernando ; Ceballos, Daniel ; Iglesias, Eva ; Gomez-Senent, Silvia ; Torres, Yolanda ; Ponferrada, Angel ; Arevalo, José A ; Hernandez, Vicent ; Calvet, Xavier ; Ginard, Daniel ; Monfort, David ; Chaparro, Maria ; Manceñido, Noemi ; Domínguez-Antonaya, Mercedes ; Villalón, César ; Perez-Calle, José L ; Muñoz, Carmen ; Nuñez, Henar ; Carpio, Daniel ; Aramendiz, Roberto ; Bujanda, Luis ; Estrada-Oncins, Silvia ; Hermida, Carlos ; Barrio, Jesus ; Casis, M Begoña ; Dueñas-Sadornil, M Carmen ; Fernández, Luis ; Calvo-Cenizo, M Mar ; Botella, Belen ; de Francisco, Ruth ; Ayala, Edgar ; Sans, Miquel</creator><creatorcontrib>Nunes, Tiago ; Barreiro-de Acosta, Manuel ; Nos, Pilar ; Marin-Jiménez, Ignacio ; Bermejo, Fernando ; Ceballos, Daniel ; Iglesias, Eva ; Gomez-Senent, Silvia ; Torres, Yolanda ; Ponferrada, Angel ; Arevalo, José A ; Hernandez, Vicent ; Calvet, Xavier ; Ginard, Daniel ; Monfort, David ; Chaparro, Maria ; Manceñido, Noemi ; Domínguez-Antonaya, Mercedes ; Villalón, César ; Perez-Calle, José L ; Muñoz, Carmen ; Nuñez, Henar ; Carpio, Daniel ; Aramendiz, Roberto ; Bujanda, Luis ; Estrada-Oncins, Silvia ; Hermida, Carlos ; Barrio, Jesus ; Casis, M Begoña ; Dueñas-Sadornil, M Carmen ; Fernández, Luis ; Calvo-Cenizo, M Mar ; Botella, Belen ; de Francisco, Ruth ; Ayala, Edgar ; Sans, Miquel ; RECLICU Study Group of GETECCU</creatorcontrib><description>Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice.
Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response.
BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p<0.0001). Remission rate was higher in mild and moderate than in severe UC (p<0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p<0.06). Failure was less frequent in patients treated for >4 weeks (p<0.02). Mild adverse events were reported in 7.6% of patients.
BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4 weeks are most likely to benefit from this treatment.</description><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1016/j.crohns.2010.07.003</identifier><identifier>PMID: 21122572</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Adult ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Beclomethasone - administration & dosage ; Beclomethasone - therapeutic use ; Colitis, Ulcerative - drug therapy ; Drug Administration Schedule ; Female ; Humans ; Male ; Remission Induction ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Journal of Crohn's and colitis, 2010-12, Vol.4 (6), p.629-636</ispartof><rights>Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083</citedby><cites>FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21122572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nunes, Tiago</creatorcontrib><creatorcontrib>Barreiro-de Acosta, Manuel</creatorcontrib><creatorcontrib>Nos, Pilar</creatorcontrib><creatorcontrib>Marin-Jiménez, Ignacio</creatorcontrib><creatorcontrib>Bermejo, Fernando</creatorcontrib><creatorcontrib>Ceballos, Daniel</creatorcontrib><creatorcontrib>Iglesias, Eva</creatorcontrib><creatorcontrib>Gomez-Senent, Silvia</creatorcontrib><creatorcontrib>Torres, Yolanda</creatorcontrib><creatorcontrib>Ponferrada, Angel</creatorcontrib><creatorcontrib>Arevalo, José A</creatorcontrib><creatorcontrib>Hernandez, Vicent</creatorcontrib><creatorcontrib>Calvet, Xavier</creatorcontrib><creatorcontrib>Ginard, Daniel</creatorcontrib><creatorcontrib>Monfort, David</creatorcontrib><creatorcontrib>Chaparro, Maria</creatorcontrib><creatorcontrib>Manceñido, Noemi</creatorcontrib><creatorcontrib>Domínguez-Antonaya, Mercedes</creatorcontrib><creatorcontrib>Villalón, César</creatorcontrib><creatorcontrib>Perez-Calle, José L</creatorcontrib><creatorcontrib>Muñoz, Carmen</creatorcontrib><creatorcontrib>Nuñez, Henar</creatorcontrib><creatorcontrib>Carpio, Daniel</creatorcontrib><creatorcontrib>Aramendiz, Roberto</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Estrada-Oncins, Silvia</creatorcontrib><creatorcontrib>Hermida, Carlos</creatorcontrib><creatorcontrib>Barrio, Jesus</creatorcontrib><creatorcontrib>Casis, M Begoña</creatorcontrib><creatorcontrib>Dueñas-Sadornil, M Carmen</creatorcontrib><creatorcontrib>Fernández, Luis</creatorcontrib><creatorcontrib>Calvo-Cenizo, M Mar</creatorcontrib><creatorcontrib>Botella, Belen</creatorcontrib><creatorcontrib>de Francisco, Ruth</creatorcontrib><creatorcontrib>Ayala, Edgar</creatorcontrib><creatorcontrib>Sans, Miquel</creatorcontrib><creatorcontrib>RECLICU Study Group of GETECCU</creatorcontrib><title>Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study</title><title>Journal of Crohn's and colitis</title><addtitle>J Crohns Colitis</addtitle><description>Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice.
Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response.
BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p<0.0001). Remission rate was higher in mild and moderate than in severe UC (p<0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p<0.06). Failure was less frequent in patients treated for >4 weeks (p<0.02). Mild adverse events were reported in 7.6% of patients.
BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4 weeks are most likely to benefit from this treatment.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Beclomethasone - administration & dosage</subject><subject>Beclomethasone - therapeutic use</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNo9kEtr3DAUhUVIaR7tPwhFu6w80cPWo7sy5AUDgbSzFrJ8TTTI1lSSA1n3j9eeSbK6h8s553I_hK4oWVFCxc1u5VJ8GfOKkXlF5IoQfoLOqZKiqmupTw-aV1rX4gxd5LwjpNGNVF_RGaOUsUayc_Rvm6Gfwgg549jjmGzALbgQByg2xxFw5_cp7n0cbQHsR1xeAJcEtgwwliVjXfGvgKfgINmDdDH44vPidsGP3s2l-7T4HPw8FDzfrjeP6y3-Xabu7Rv60tuQ4fv7vETbu9s_64dq83T_uP61qRxvWKk60IoykIq7FnjPrCKEOQaUqdYCVdQ2tAUreimF7q1uaiZE2_SCC806ovgluj72zg_9nSAXM_jsIAQ7QpyyUVQJroWsZ2d9dM6Ic07Qm33yg01vhhKz0Dc7c6RvFvqGSDPTn2M_3g9M7QDdZ-gDN_8Pz9qEsg</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Nunes, Tiago</creator><creator>Barreiro-de Acosta, Manuel</creator><creator>Nos, Pilar</creator><creator>Marin-Jiménez, Ignacio</creator><creator>Bermejo, Fernando</creator><creator>Ceballos, Daniel</creator><creator>Iglesias, Eva</creator><creator>Gomez-Senent, Silvia</creator><creator>Torres, Yolanda</creator><creator>Ponferrada, Angel</creator><creator>Arevalo, José A</creator><creator>Hernandez, Vicent</creator><creator>Calvet, Xavier</creator><creator>Ginard, Daniel</creator><creator>Monfort, David</creator><creator>Chaparro, Maria</creator><creator>Manceñido, Noemi</creator><creator>Domínguez-Antonaya, Mercedes</creator><creator>Villalón, César</creator><creator>Perez-Calle, José L</creator><creator>Muñoz, Carmen</creator><creator>Nuñez, Henar</creator><creator>Carpio, Daniel</creator><creator>Aramendiz, Roberto</creator><creator>Bujanda, Luis</creator><creator>Estrada-Oncins, Silvia</creator><creator>Hermida, Carlos</creator><creator>Barrio, Jesus</creator><creator>Casis, M Begoña</creator><creator>Dueñas-Sadornil, M Carmen</creator><creator>Fernández, Luis</creator><creator>Calvo-Cenizo, M Mar</creator><creator>Botella, Belen</creator><creator>de Francisco, Ruth</creator><creator>Ayala, Edgar</creator><creator>Sans, Miquel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101201</creationdate><title>Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study</title><author>Nunes, Tiago ; Barreiro-de Acosta, Manuel ; Nos, Pilar ; Marin-Jiménez, Ignacio ; Bermejo, Fernando ; Ceballos, Daniel ; Iglesias, Eva ; Gomez-Senent, Silvia ; Torres, Yolanda ; Ponferrada, Angel ; Arevalo, José A ; Hernandez, Vicent ; Calvet, Xavier ; Ginard, Daniel ; Monfort, David ; Chaparro, Maria ; Manceñido, Noemi ; Domínguez-Antonaya, Mercedes ; Villalón, César ; Perez-Calle, José L ; Muñoz, Carmen ; Nuñez, Henar ; Carpio, Daniel ; Aramendiz, Roberto ; Bujanda, Luis ; Estrada-Oncins, Silvia ; Hermida, Carlos ; Barrio, Jesus ; Casis, M Begoña ; Dueñas-Sadornil, M Carmen ; Fernández, Luis ; Calvo-Cenizo, M Mar ; Botella, Belen ; de Francisco, Ruth ; Ayala, Edgar ; Sans, Miquel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Beclomethasone - administration & dosage</topic><topic>Beclomethasone - therapeutic use</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nunes, Tiago</creatorcontrib><creatorcontrib>Barreiro-de Acosta, Manuel</creatorcontrib><creatorcontrib>Nos, Pilar</creatorcontrib><creatorcontrib>Marin-Jiménez, Ignacio</creatorcontrib><creatorcontrib>Bermejo, Fernando</creatorcontrib><creatorcontrib>Ceballos, Daniel</creatorcontrib><creatorcontrib>Iglesias, Eva</creatorcontrib><creatorcontrib>Gomez-Senent, Silvia</creatorcontrib><creatorcontrib>Torres, Yolanda</creatorcontrib><creatorcontrib>Ponferrada, Angel</creatorcontrib><creatorcontrib>Arevalo, José A</creatorcontrib><creatorcontrib>Hernandez, Vicent</creatorcontrib><creatorcontrib>Calvet, Xavier</creatorcontrib><creatorcontrib>Ginard, Daniel</creatorcontrib><creatorcontrib>Monfort, David</creatorcontrib><creatorcontrib>Chaparro, Maria</creatorcontrib><creatorcontrib>Manceñido, Noemi</creatorcontrib><creatorcontrib>Domínguez-Antonaya, Mercedes</creatorcontrib><creatorcontrib>Villalón, César</creatorcontrib><creatorcontrib>Perez-Calle, José L</creatorcontrib><creatorcontrib>Muñoz, Carmen</creatorcontrib><creatorcontrib>Nuñez, Henar</creatorcontrib><creatorcontrib>Carpio, Daniel</creatorcontrib><creatorcontrib>Aramendiz, Roberto</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Estrada-Oncins, Silvia</creatorcontrib><creatorcontrib>Hermida, Carlos</creatorcontrib><creatorcontrib>Barrio, Jesus</creatorcontrib><creatorcontrib>Casis, M Begoña</creatorcontrib><creatorcontrib>Dueñas-Sadornil, M Carmen</creatorcontrib><creatorcontrib>Fernández, Luis</creatorcontrib><creatorcontrib>Calvo-Cenizo, M Mar</creatorcontrib><creatorcontrib>Botella, Belen</creatorcontrib><creatorcontrib>de Francisco, Ruth</creatorcontrib><creatorcontrib>Ayala, Edgar</creatorcontrib><creatorcontrib>Sans, Miquel</creatorcontrib><creatorcontrib>RECLICU Study Group of GETECCU</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nunes, Tiago</au><au>Barreiro-de Acosta, Manuel</au><au>Nos, Pilar</au><au>Marin-Jiménez, Ignacio</au><au>Bermejo, Fernando</au><au>Ceballos, Daniel</au><au>Iglesias, Eva</au><au>Gomez-Senent, Silvia</au><au>Torres, Yolanda</au><au>Ponferrada, Angel</au><au>Arevalo, José A</au><au>Hernandez, Vicent</au><au>Calvet, Xavier</au><au>Ginard, Daniel</au><au>Monfort, David</au><au>Chaparro, Maria</au><au>Manceñido, Noemi</au><au>Domínguez-Antonaya, Mercedes</au><au>Villalón, César</au><au>Perez-Calle, José L</au><au>Muñoz, Carmen</au><au>Nuñez, Henar</au><au>Carpio, Daniel</au><au>Aramendiz, Roberto</au><au>Bujanda, Luis</au><au>Estrada-Oncins, Silvia</au><au>Hermida, Carlos</au><au>Barrio, Jesus</au><au>Casis, M Begoña</au><au>Dueñas-Sadornil, M Carmen</au><au>Fernández, Luis</au><au>Calvo-Cenizo, M Mar</au><au>Botella, Belen</au><au>de Francisco, Ruth</au><au>Ayala, Edgar</au><au>Sans, Miquel</au><aucorp>RECLICU Study Group of GETECCU</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study</atitle><jtitle>Journal of Crohn's and colitis</jtitle><addtitle>J Crohns Colitis</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>4</volume><issue>6</issue><spage>629</spage><epage>636</epage><pages>629-636</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><abstract>Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice.
Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response.
BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p<0.0001). Remission rate was higher in mild and moderate than in severe UC (p<0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p<0.06). Failure was less frequent in patients treated for >4 weeks (p<0.02). Mild adverse events were reported in 7.6% of patients.
BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4 weeks are most likely to benefit from this treatment.</abstract><cop>England</cop><pmid>21122572</pmid><doi>10.1016/j.crohns.2010.07.003</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1873-9946 |
| ispartof | Journal of Crohn's and colitis, 2010-12, Vol.4 (6), p.629-636 |
| issn | 1873-9946 1876-4479 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_818639674 |
| source | Oxford Journals Online |
| subjects | Administration, Oral Adult Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Beclomethasone - administration & dosage Beclomethasone - therapeutic use Colitis, Ulcerative - drug therapy Drug Administration Schedule Female Humans Male Remission Induction Retrospective Studies Severity of Illness Index Treatment Outcome |
| title | Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A07%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%20oral%20beclometasone%20dipropionate%20in%20the%20treatment%20of%20active%20ulcerative%20colitis%20in%20clinical%20practice:%20the%20RECLICU%20Study&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Nunes,%20Tiago&rft.aucorp=RECLICU%20Study%20Group%20of%20GETECCU&rft.date=2010-12-01&rft.volume=4&rft.issue=6&rft.spage=629&rft.epage=636&rft.pages=629-636&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1016/j.crohns.2010.07.003&rft_dat=%3Cproquest_cross%3E818639674%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c352t-de9812e783cbe3f2a8002c2e128bae181a51bea6f7769fa954266b5f63692d083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=818639674&rft_id=info:pmid/21122572&rfr_iscdi=true |